"The revenue benchmarks associated with the performance share scheme applying to Wilkins and Holton always seemed ridiculously soft".. I posted thi sin the IPO thread before it listed but even with those performance shares being given, the company was still very good value.
- Forums
- ASX - By Stock
- SP3
- Ann: Change in substantial holding - Wilkins
Ann: Change in substantial holding - Wilkins, page-10
-
-
- There are more pages in this discussion • 35 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SP3 (ASX) to my watchlist
(20min delay)
|
|||||
Last
2.3¢ |
Change
0.002(9.52%) |
Mkt cap ! $5.617M |
Open | High | Low | Value | Volume |
2.3¢ | 2.3¢ | 2.3¢ | $1.241K | 53.93K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 165000 | 2.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.3¢ | 114543 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 165000 | 0.021 |
1 | 500000 | 0.020 |
2 | 110000 | 0.019 |
3 | 568647 | 0.018 |
4 | 1158050 | 0.017 |
Price($) | Vol. | No. |
---|---|---|
0.023 | 114543 | 1 |
0.029 | 48180 | 1 |
0.030 | 33365 | 1 |
0.031 | 31580 | 1 |
0.034 | 7000 | 1 |
Last trade - 15.48pm 15/07/2024 (20 minute delay) ? |
Featured News
SP3 (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online